Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol 2014; 20(28): 9486-9496 [PMID: 25071343 DOI: 10.3748/wjg.v20.i28.9486]
Corresponding Author of This Article
Xue-Song Liang, Associate Professor, Department of Infectious Diseases, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. liangxuesong2000@163.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Cheng-Zhong Li, Jian-Ya Xue, Wei Yin, Ya-Yun Liu, Wen-Han Fan, Hao Xu, Xue-Song Liang, Department of Infectious Diseases, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Jing-Jing Hu, Central Laboratory, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Author contributions: Li CZ and Hu JJ contributed equally to this work; Li CZ collected all human materials and helped draft the manuscript; Hu JJ performed most of the experiments; Xue JY, Yin W, Liu YY, Fan WH and Xu H were responsible for enrolling and following the patients; Liang XS conceived the study, participated in the study design, performed statistical analysis and drafted the manuscript; all authors have read and approved the final manuscript.
Supported by The Shanghai Natural Science Fund, No. 09ZR1400500; the National Natural Science Foundation of China, No. 30972600; the GuangHui Fund of Hepatitis Prevention Fund Committee China, No. GHZ20100204; and the Shanghai Health Bureau Fund, No. 2012092
Correspondence to: Xue-Song Liang, Associate Professor, Department of Infectious Diseases, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. liangxuesong2000@163.com
Telephone: +86-21-31161902 Fax: +86-21-65518368
Received: December 4, 2013 Revised: February 8, 2014 Accepted: April 1, 2014 Published online: July 28, 2014
Core Tip
Core tip: We compared the host immunity of hepatitis B envelope antigen (HBeAg)-positive patients treated with telbivudine (LDT) to those treated with lamivudine (LAM) and longitudinally investigated the relationship between two important negative immune modulating factors and viral infection parameters in HBeAg-positive chronic hepatitis B (CHB) patients that were treated with the nucleoside analogues (NAs) LDT and LAM. NA-mediated inhibition of hepatitis B virus replication could cause the downregulation of PD-1+ CD8 T cells and Treg cells during the first 24 wk of therapy and could also partially restore the ability of CD8 T cells to secrete pro-inflammatory cytokines. The immune modulating effect associated with NA treatment in CHB patients was correlated with the levels of both HBV DNA and HBeAg.
